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Down syndrome is a complex condition caused by trisomy of human chromosome 21. The biology of aging may be diﬀerent in
individuals with Down syndrome; this is not well understood in any organism. Because of its complexity, many aspects of Down
syndrome must be studied either in humans or in animal models. Studies in humans are essential but are limited for ethical and
practical reasons. Fortunately, genetically altered mice can serve as extremely useful models of Down syndrome, and progress in
their production and analysis has been remarkable. Here, we describe various mouse models that have been used to study Down
syndrome. We focus on segmental trisomies of mouse chromosome regions syntenic to human chromosome 21, mice in which
individual genes have been introduced, or mice in which genes have been silenced by targeted mutagenesis. We selected a limited
number of genes for which considerable evidence links them to aspects of Down syndrome, and about which much is known
regarding their function. We focused on genes important for brain and cognitive function, and for the altered cancer spectrum
seen in individuals with Down syndrome. We conclude with observations on the usefulness of mouse models and speculation on
future directions.
1.Why Use Mouse Models?
Down syndrome (DS) is diagnosed by chromosome analysis,
either prenatally (usually because of identiﬁed risk factors),
or postnatally (typically because of the appearance of the
infant). The DS phenotype is complicated and variable, thus
models of DS must be able to address this complexity and
variability.
Intellectual disability may be the most well-known fea-
ture of DS, but it is accompanied by behavioral, psychiatric,
and neurological problems. In early infancy, people with
DS function in the range of low typical development, but
the intelligence quotient decreases in the ﬁrst ten years
of life, reaching a plateau in adolescence that extends
into adulthood. Learning is complicated by a tendency to
avoid cognitive challenges, and by a deﬁciency in language
production. About 17.6% of individuals with DS less than
20 years of age have a psychiatric disorder, most often
a disruptive behavioral disorder, such as attention deﬁcit
hyperactivity disorder, conduct/oppositional disorder, or
aggressive behavior. About 25.6% of adults have a psychiatric
disorder, most frequently depression or aggressive behavior.
People with DS have a higher incidence of autism. By the
ﬁfth decade of life, neuropathological changes typical of
Alzheimer’s disease (AD) usually develop. Clinical signs and
symptoms of AD are seen in 75% of people over 60 years of
age. These are usually seizures, changes in personality, focal
neurological signs, apathy, and loss of conversational skills
[1].
The complexity of DS extends well beyond mental
and neurological issues. For example, about half of people
with DS are born with congenital heart disease, and heart
disease can develop (or be initially identiﬁed) later in life.
Adolescents and young adults with no known intracar-
diac disease can develop mitral valve prolapse and aortic
regurgitation. People with DS are more likely to have2 Current Gerontology and Geriatrics Research
hematological disorders. These include polycythaemia in
newborns, macrocytosis, transient myeloproliferative dis-
order, acute myeloid leukemia, and acute lymphoblastic
leukemia. Between 38% and 78% of people with DS have
conductive and/or sensorineural hearing loss. About 38%
of children less than 12 months of age, and 80% age 5 to
12, have ophthalmological disorders requiring monitoring
and intervention. The most frequent disorders are refractive
errors, strabismus, and nystagmus. Resting metabolic rates
are reduced in individuals with Downs syndrome, which
results in a higher frequency of obesity, and children at ages 3
to 4 are more likely to be obese than not. Monitoring intake
of calcium and vitamin D is important, since individuals
with DS exhibit lower bone density. People with DS have
a higher incidence of coeliac disease and hypothyroidism.
Many disorders, such as arthritis, atlantoaxial subluxation,
diabetes mellitus, leukemia, obstructive sleep apnea, and
seizures, occur more frequently among individuals with DS
than in the general population [1].
Given the complexity of the DS phenotype, computer
models, in vitro models, models based on lower organisms,
and so forth, are woefully inadequate for representing
DS. Mouse models have many characteristics that make
them well suited to the study of DS. First, mice are a
higher organism with the requisite biological characteristics.
Neurological, behavioral, cardiac, hematological, skeletal
disorders, and so forth, can be studied using mouse models.
Second, they are very well characterized. Mouse models
have been extensively used in research, and a great deal
is known about them. Additionally, they are commonly
used in development and testing of drugs for treatment
of various disorders, including ones associated with DS.
Third, there are numerous practical issues that make mouse
models especially attractive. Mice are small, they have a
relatively short generation time, they reproduce rapidly, are
inexpensive to maintain and house, and are easy to handle.
2.What Deﬁnes aDSMouse Model?
Various genetically altered mice have been proposed as
mouse models of DS, and rapid progress is being made
creating new models. An important point to bear in mind
is that no mouse model will be a perfect model of DS. Even
though mice have many similarities to humans, there are
signiﬁcant, and obvious, diﬀerences; therefore, some aspects
of DS simply cannot be adequately modeled in mice. For
example, it is clear that one can use mice to study aspects of
learning and memory, but they cannot serve as a complete
model for human intellect. Mice have their own sets of
behaviors that have been selected for over evolutionary time,
and some of these behaviors are not relevant to studies of
humans, with or without DS.
There are clear biochemical and metabolic diﬀerences
between mice and humans as well, even though basic
biochemical pathways have been conserved. For example,
in humans, the end product of purine metabolism is uric
acid, which is an antioxidant that may be relevant to
the oxidative stress associated with DS. Indeed, individuals
with DS accumulate unusually high levels of uric acid in
their blood [2], which may be important in aging, and in
neurodegenerative diseasesassociatedwithaging andDS[3].
ThismaybeduetotrisomyoftheGARTgene,whichencodes
an enzyme that catalyzes 3 steps of de novo purine synthesis,
or it may be due to abnormal processing of uric acid by
the kidneys of individuals with DS, or perhaps some other
unknown mechanism. Mice, on the other hand, metabolize
uric acid to allantoin, which is much more soluble and
easily excreted. Therefore, modeling alterations in purine
metabolism in mice may be diﬃcult unless this metabolic
diﬀerence is taken into account. One approach would be to
use mice lacking uricase that accumulate uric acid as the end
product of purine metabolism [4].
Anotherexampleisthatmicemetabolizefolicacidsome-
what diﬀerently than humans. Folate levels are about 10 fold
higher in murine versus human plasma [5]. Therefore, alter-
ations in folate metabolism in mice may not have the same
metabolic consequences as similar alterations in humans.
Abnormalities in folate metabolism or polymorphisms in
genes encoding enzymes of folate metabolism have been
associatedwithDSinmanystudies,althoughthesigniﬁcance
of these polymorphisms is still unclear [6]. Adding to this
complexity, it may be that particular polymorphisms in
individual steps of folate metabolism may function only
in the context of other polymorphisms, and that various
suites of polymorphisms may have similar eﬀects, making
it diﬃcult to compare studies [7]. Recent evidence also
demonstrates that alterations in folate metabolism may be
associated with speciﬁc aspects of DS, such as congenital
heart disease [8]. Folate metabolism may also be related to
thebiologyofagingandage-relateddisorders[9,10].Impor-
tantly, several genes necessary for folate metabolism reside
onHSA21,includingcystathioninebetasynthase(CBS)[11].
Mutations in CBS are clearly associated with intellectual
disability and cardiovascular disease [12]. The reduced folate
carrier (Slc19a1), which is important for traﬃcking of folates
in mammals, is also located on HSA21 [13]. Mutations or
polymorphisms in Slc19a1 are associated with sensitivity to
methotrexate[14].Ithasbeenhypothesizedthatthepresence
of 3 copies of Slc19a1 in persons with DS may be partly
responsible for their unusual sensitivity to folate analogues
[15] .I nt h em o u s eg e n o m e ,C B Sm a p st oM m u 1 7a n d
Slc19a1 to Mmu10 (regions syntenic to HSA21). Numerous
mouse models with alterations in CBS or Slc19a1 have been
produced, including mice in which the endogenous mouse
gene has been inactivated and replaced by the equivalent
human gene [16–18]. So far, it has been diﬃcult to learn
much about human DS from studying these mice. The fact
thatthesegenesarepresentondiﬀerentmousechromosomes
complicates the production of appropriate mouse models
that are relevant to human DS.
Although Mmu16, 17, and 10 contain essentially all the
known genes on HSA21, they are not completely analogous
to HSA21. Some of the genes may be species speciﬁc in
both humans and mice, and the chromosome regions may
have regulatory sequences or copy number variations that
may not encode proteins but are nonetheless important for
phenotypic development. Sturgeon and Gardiner [19]h a v eCurrent Gerontology and Geriatrics Research 3
publishedanexcellentcomparisonoftherelevantmouseand
human genetic regions (along with chimpanzee), and the
interested reader is referred to that work for further details.
An additional consideration is that manipulation of
the mouse genome may have unexpected consequences. As
discussed below, some trisomy mouse models have recently
been shown to have unexpected additional chromosomal
alterations.
Nonetheless, several diﬀerent types of mouse models
have been extremely useful in investigating aspects of DS,
and models are becoming more accurate and sophisticated.
Therefore, analysis of various types of mouse models is likely
to be increasingly important in unraveling speciﬁc aspects of
DS, with diﬀerent types of models having diﬀerent roles.
It is important to carefully consider the usefulness of
mouse models that clearly show phenotypes relevant to
DS. Speciﬁcally, if a particular mouse model of DS has a
phenotype(s) reminiscent of DS, is the model appropriate
for investigating DS? As clinical trials based on studies of
various mouse models become more common, this becomes
an exceedingly important question (see Section 5).
Even mice that do not show a phenotype reminiscent of
DS may be quite useful in understanding DS. For example,
mice in which a particular HSA21 syntenic gene has been
inactivated by targeted mutagenesis may be crucial for
understanding the function of that gene, informing under-
standing of its role in DS. Large-scale projects to inactivate
everymousegeneindividuallyandtoevaluatethephenotype
of each of the knockout mice are underway and should be
extremely helpful in understanding the role of these genes
in the DS phenotype (http://www.mousephenotype.org/).
Moreover, these mice are useful in manipulating gene copy
number in mice that are trisomic for particular Mmu chro-
mosomal regions syntenic to HSA21. Comparison of several
diﬀerent models can increase conﬁdence that phenotypes
reminiscent of DS relate to human DS in a meaningful way.
This approach was suggested in the ﬁrst description of the
isolation of the Ts65Dn mouse model, discussed below [20].
Inthisreview,wehaveselectedafewillustrativeexamples
of mouse models of DS from the large number that exist.
We describe mice trisomic for various regions of HSA21
or the mouse chromosomal regions syntenic to HSA21,
selected transgenic (Tg) mice, and selected mice in which
speciﬁcgeneshavebeeninactivated(knockout,orKO,mice).
Further, where possible, we describe combinations of these
models. We have focused primarily on genes for which
both Tg and KO mice exist, and where KO mice have
been combined with trisomic mice to elucidate function
by restoring disomy. In this way, we have attempted to
describe the wide range of options available in utilizing
mouse models to study DS. We have also chosen genes that
appear to be functionally related, for which considerable
information regarding function is known, and that appear
to be related to important DS phenotypes. Thus, we focus
on the APP, RCAN1, and SYNJ1 genes because these appear
to be important for synaptic plasticity and/or function, and
are likely to be related to the intellectual disabilities seen in
individualswithDS.WehavealsochosenRUNX1,ETS2,and
ERG,agroupofgenesthatarerelevanttocancer.Thesegenes
are likely to be related to the altered incidence of cancer seen
in individuals with DS.
3. Typesof DSMouse Models
3.1. Chromosomal Trisomy Mice. Mice trisomic for chro-
mosome regions syntenic to HSA21, and mice that carry
regions of HSA21, may be more complete models of the DS
phenotype, since they are trisomic for many genes trisomic
in individuals with DS. On the other hand, trisomy of
multiplegenesmakesinterpretationofresultsmorecomplex.
Numerous trisomic or transchromosomal mice have been
produced. With the advent of chromosome engineering
approaches, it is now possible to produce mice trisomic
for any chromosome region. Figure 1 shows a graphical
representation of the chromosome regions present in these
models, and a representation of HSA21 and the syntenic
mouse chromosome regions.
3.1.1. Ts16. The ﬁrst mouse model of DS was the Ts16
mouse, which is trisomic for essentially all of Mmu16, in-
cluding the part of Mmu16 syntenic to HSA21. These mice
were produced by Alfred Gropp using a mouse breeding
scheme that is selected for mice with centric fusions [21].
Several investigators, notably Dr. Charles Epstein, noted that
some features of these mice were reminiscent of DS and
hypothesized that these mice might present a model for
certain aspects of DS [22]. This hypothesis was supported
whenseveralgenesknowntobelocatedonHSA21,including
SOD1, IFNAR, and GART, were found to be on Mmu16 [23–
25]. This was the ﬁrst evidence that mouse models of DS
could be created.
Unfortunately, the Ts16 mice generally die during fetal
development or very shortly after birth. Thus, they have
proven useful for the study of embryonic/fetal development
but are not very helpful for studies of aspects of DS during
the lifespan, and certainly not for aspects of DS relevant
to aging. However, cell lines derived from Ts16 mice have
been used to study biological processes related to DS and
potentially relevant to aging and age-related disorders [26,
27]. An important caveat is that the Ts16 mice are trisomic
for many Mmu16 genes that are not located on HSA21.
3.1.2. Ts65Dn and Derivatives. The production by Muriel
Davisson and colleagues of a mouse trisomic for only part
of Mmu16, now known as the Ts65Dn mouse, was a seminal
achievement in DS research [20]. They produced these mice
by irradiating the testes of male mice, breeding them, and
screeningoﬀspringforchromosomalrearrangementsinvolv-
ing Mmu16. The Ts65Dn mouse is trisomic for roughly 94
genes syntenic to well-curated HSA21 genes, although this
number is subject to change as analysis of the complete
human and mouse genomic sequences continues [28]. It is
the most well characterized and widely studied mouse model
of DS. It is important to note that the Ts65Dn mouse is
disomic for about 16 HSA21/Mmu16 genes [29], and it has
recently been shown that these mice are also trisomic for a
centromere proximal region of Mmu17. The chromosomal4 Current Gerontology and Geriatrics Research
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Figure 1: A graphical representation of HSA21 and the syntenic mouse chromosome regions from Mmu10, Mmu16, and Mmu17. The
trisomic (or monosomic) chromosome regions present in 10 of the segmental mouse trisomies are also shown, with color-coding indicating
the chromosome source of the region (see the key in the ﬁgure). The location of 11 HSA21 genes is shown, as well as their location on the
syntenic chromosome regions, with text color indicating which syntenic chromosome. The dark ovals indicate the HSA21 centromere.
rearrangement site between Mmu16 and Mmu17 has been
precisely deﬁned [30, 31], and it turns out that Ts65Dn
mice are trisomic for up to 60 Mmu17 genes, many of
whichareoverexpressedinheart.Notably,twoMmu17genes
trisomic in Ts65Dn mice include Synj2 and Tiam2, which
are related to the HSA21/Mmu16 encoded genes Synj1 and
Tiam1. The phenotype of the Ts65Dn mouse is quite similar
to the phenotype of mice trisomic for the entire region of
Mmu16 syntenic to HSA21, and indeed to mice trisomic for
allmousechromosomeregionspresentonHSA21(discussed
in more detail below). One diﬀerence between Ts65Dn mice
and these models is that the trisomic region in Ts65Dn is
present as a freely segregating extra chromosome, while in
other models, the relevant chromosome region has been
duplicated by chromosome engineering methods or in two
cases (Ts1Cje and Ts2Cje) serendipitously. It has been argued
that the presence of an extra chromosome in the Ts65Dn
mice may make them a more acceptable model of DS. This
proposal needs to be considered in light of observations on
humans with DS due to translocations (i.e., not a freely
segregating extra chromosome 21). The vast majority of
these are Robertsonian translocations involving centromeric
fusions [32]. Also, there are several examples of apparently
balanced translocations between HSA21 and other human
chromosomes that do not involve centromeres, resulting in
an apparently classical DS phenotype [33–35]. Therefore, at
least for phenotypes not related to reproduction, it seems
that in humans the presence of an extra chromosome is not
necessary for DS.
Ts65Dn mice have many features reminiscent of those
seen in people with DS. These include anatomical features
such as small brain regions (notably the hippocampus and
cerebellum) and abnormal skull shape [36]. Other similari-
ties include congenital heart defects [37], myeloproliferative
disorders [38], decreased bone density [39], and altered
incidence and response to certain cancers [40, 41]. Most
notably, Ts65Dn mice exhibit deﬁcits in learning, memory
and behavior, as well as aspects of early neurodegeneration
t h a tm a yb er e l e v a n tt oe a r l yf e a t u r e so fA Da sw e l la sa g i n g
[42, 43].
Ts65Dn mice show signs of what might be called
premature aging and neurodegeneration. They show early
loss of basal forebrain cholinergic neurons that may be
related to loss of learning and memory ability in theseCurrent Gerontology and Geriatrics Research 5
mice [42, 43]. Although the mice are trisomic for APP,
they do not develop plaques or tangles characteristic of AD
in humans or transgenic mouse models of this disorder.
However, they do show increased expression of the APP
gene and increased levels of the products of APP protein
metabolism with age [44]. Moreover, old Ts65Dn mice
accumulate tau/reelin containing clusters in the CA1 region
of the hippocampus and extracellular tau/reelin granular
deposits [45]. Similar deposits have been observed in mouse
models of AD. Systemic aging has been examined in Ts65Dn
mice, and there are indications that certain aspects of aging
may be accelerated, for example, increased risk of lymphoma
[46].
A number of treatments apparently improve learning
and memory in Ts65Dn or prevent their decline [28]. Some
of these are of particular relevance to the possibility of
premature aging in these mice. For example, memantine,
a drug used in humans to treat AD, appears to improve
learning and memory in Ts65Dn [47–49]. Treatment of
young (4 month old) Ts65Dn mice with a gamma secretase
inhibitor has been reported to rescue learning and memory,
potentially implicating the amyloid precursor protein (APP)
or its metabolites in learning and memory deﬁcits, even at an
early age [50]. At least two laboratories have demonstrated
that treatment with vitamin E can ameliorate learning and
memory decline with age and concomitantly reduce signs
of oxidative stress in the brains of Ts65Dn mice [51, 52].
One study suggests that vitamin E treatment is most useful
if given perinatally and throughout life [52]. These ﬁndings
are particularly relevant because numerous studies on the
possible beneﬁcial eﬀects of vitamin E treatment on humans
with AD and on humans with DS have been published
or are underway. Although an early study appeared to
show that large doses of vitamin E (2000IU/day) slowed
the loss of activities of daily living of persons with AD
by about 11 months, other studies have not shown an
eﬀect, and the statistical signiﬁcance of the initial study has
been questioned [53–55] .Ar e c e n tp u b l i c a t i o np r o v i d e sa n
interesting discussion of why human trials of vitamin E fail
[56]. One obvious issue is that studies in which treatment
has started after disease onset may fail because irreversible
damage has already been done. This is consistent with
studies suggesting that lifelong vitamin E supplementation
of Ts65Dn mice may be most eﬀective.
A recent study also indicates that choline supplemen-
tation during pregnancy and lactation improves aspects
of learning and memory and emotion regulation in adult
Ts65Dn oﬀspring [57]. This is consistent with earlier reports
that prenatal choline supplementation improves the learning
and memory of diploid rats, well into adulthood [58, 59].
More recent studies show that perinatal choline supple-
mentation has beneﬁcial eﬀects on the development of the
hippocampus in mice as well [60, 61]. These studies did
not assess the long-term eﬀects of perinatal choline sup-
plementation on mouse behavior or learning and memory.
This eﬀect may be related to the cholinergic deﬁcits seen in
Ts65Dn mice.
Several other treatments, including ﬂuoxetine, PTZ, pro-
drugs for norepinephrine, xamoterol, and perhaps lithium
and voluntary exercise, improve certain aspects of the
Ts65Dn phenotype.
There have been a number of models derived from
Ts65Dn mice. Some of these overcome speciﬁc weaknesses
in the Ts65Dn model. For example, Ts65Dn mice carry a
gene for retinal degeneration, which means some mice are
blind and cannot be used for tests requiring vision. The gene
has now been bred out of the Ts65Dn mice, and these mice
appear otherwise to be essentially equivalent to the original
Ts65Dn [62]. A second weakness of the Ts65Dn mouse is
that males generally are functionally sterile. Ts2Cje mice are
a Ts65Dn derivative in which the extra chromosome of the
Ts65Dn mice has undergone a Robertsonian translocation
with Mmu12 [63] .T h e s em i c ea p p e a rt ob r e e dw e l l ,a n d
males have increased, though still diminished, fertility.
Recently, the Reeves laboratory has reported a method for
breeding large numbers of Ts65Dn mice from Ts65Dn males
[64].
3.1.3. Ts1Cje. The Ts1Cje mouse is trisomic for a shorter
region of Mmu16 than the Ts65Dn mouse, containing
roughly 75 genes syntenic to well-curated genes located
on HSA21. This mouse is the consequence of an attempt
to inactivate Sod1 by targeted mutagenesis, resulting in a
translocation between Mmu16 and Mmu12. The Sod1 gene
is inactivated in these mice. It has recently been shown that
this mouse is monosomic for seven Mmu12 genes [30, 65].
Two of these, Abcb5 and Itgb8, are related to the HSA21
genes ABCG1 (located on Mmu17), and CD18 (located on
Mmu10). Neither of these is trisomic in Ts65Dn or Ts1Cje.
The Ts1Cje mice are disomic for 19 genes that are
trisomic in Ts65Dn (or Ts2Cje, which is apparently genet-
ically equivalent, see Section 3.1.2) mice, including APP
and SOD1. Therefore, a useful approach is to compare
features associated with DS in the Ts2Cje and Ts1Cje mice.
Presumably, diﬀerences between the two mouse strains are
due to the diﬀerence in gene copy number, and common
features are due to the common set of trisomic genes.
An interesting comparison of Ts1Cje and the Ts2Cje mice
indicatesthatbothstrainsshareenlargedbrainventriclesand
decreased neurogenesis [66]. On the other hand, learning
deﬁcits in Ts1Cje appear to be less severe than in Ts2Cje,
and degeneration of basal forebrain cholinergic neurons
is absent [67]. However, several neuroanatomical features
related to DS, like regionally selective decrease in dendritic
spines, are present in Ts1Cje but are less severe [68]. Given
the recent recognition of the extent of trisomy of Mmu17
genes in Ts65Dn and the monosomy of Mmu12 genes in
Ts1Cje, caution is necessary in interpreting the results of
these comparisons. Moreover, as discussed above, it should
be kept in mind that Ts65Dn mice are aneuploid and have a
freeextrachromosome,whileTs1CjeandTs2Cje(andseveral
of the mice described below) do not. The possibility exists
that the presence of the extra chromosome in Ts65Dn mice
may aﬀect their phenotype [30].
An example of the usefulness of the Ts1Cje model has
to do with the hypothesis that SOD1 and APP may be6 Current Gerontology and Geriatrics Research
important for oxidative stress, mitochondrial dysfunction,
and tau hyperphosphorylation, perhaps associated with
premature aging and neurodegeneration. It appears that all
these features are observed in the Ts1Cje mouse model even
though APP and SOD1 are functionally diploid in these
mice [69]. Presumably other genes trisomic (or possibly
monosomic) in Ts1Cje play a role in these abnormalities.
Rapamycin, an inhibitor of mammalian target of
rapamycin (mTOR), has recently been shown to extend
the health span and lifespan of diploid, noninbred mice
[70, 71]. mTOR is a key regulator of metabolism and of
dendritic morphology and synaptic plasticity. Interestingly,
in Ts1Cje mice, levels of BDNF and phosphorylated Akt-
mTOR are elevated. This results in abnormally high local
dendritic protein translation, thought to play a key role
in memory formation. Treatment of Ts1Cje neurons with
rapamycin repairs this defect [72]. These ﬁndings suggest
the possibility that rapamycin, or other inhibitors of mTOR,
might be useful in treatment of learning and memory loss
and intellectual disability in DS.
3.1.4. Ts1Rhr and Related Mice. Mouse models have the
potential to contribute to the question of genotype-phe-
notype mapping in DS. Appropriately constructed mouse
models should be useful for testing whether the postulated
Down Syndrome Critical Region (DSCR, a small region
of HSA21 critical for the development of DS) exists [73,
74]. Olson et al. [75] used chromosome engineering to
produce the Ts1Rhr mouse, which is trisomic for the
mouse equivalent of the hypothetical human DSCR. This
region includes about 33 genes. In their initial report, it
was shown that this mouse DSCR is not suﬃcient and,
by examining mice monosomic for this region, largely
unnecessary for the craniofacial phenotype seen in Ts65Dn
mice and in people with DS. In later studies [76], it was
shown that trisomy of the DSCR alone is necessary, but
not suﬃcient, for the structural and learning and memory
deﬁcits (assessed by the Morris water maze) seen in Ts65Dn
mice and in DS. However, a later, more comprehensive
study utilizing behavioral tests considered more sensitive
than the Morris water maze test revealed that the situation
is considerably more complex than initially thought [77]. In
this study, using the same mice, trisomy of this region was
found suﬃcient to confer behavioral, neurophysiological,
and synaptic phenotypes characteristic of DS. In all, 20
of 48 features related to DS were altered; however, some
changes were less severe than in Ts65Dn (or Ts1Cje) mice.
Moreover, the Ts1Rhr mice showed phenotypes that are not
observed in Ts65Dn or other models, including increased
body and brain weight and a larger posterior hippocampal
region compared to diploid mice, which is not seen in DS
and in Ts65Dn or Ts1Cje mice. The authors suggest that
these ﬁndings may mean that people with partial trisomy
21 may have phenotypes not seen in full trisomy 21. As
mentioned above, Ts65Dn mice have reduced bone density
[39]. Ts1Rhr mice do not exhibit this phenotype, and mice
monosomic for this region show decreased bone density
[78]. These experiments illustrate the complexity of the DS
phenotype and reinforce the concept that study of diﬀerent
mouse models is important for developing an understanding
of how DS develops.
3.1.5. Ts1Yah. Ts1Yah mice are trisomic for the HSA21
syntenic region on Mmu17 between Abcg1 and U2af1,
which contains 12 genes [79] .T h e s em i c eh a v es e v e r a l
interesting features. They have learning and memory deﬁcits
as measured by the open ﬁeld, Y arm maze, and novel
object recognition tests. However, they appear to learn
more eﬃciently in the Morris water maze test than diploid
mice. They also have larger and longer lasting long-term
potentiation (LTP) responses than diploid control mice,
probably related to their improved performance on the
Morris water maze. This is a provocative ﬁnding that clearly
supports the hypothesis that interaction of many regions
of HSA21 is required for the DS phenotype. Indeed, as the
authors point out, trisomy of certain genes or regions of
HSA21 may actually improve some aspects of cognition.
Such a compensatory mechanism has been hypothesized to
exist in human DS as well [80].
Ts1Yah mice also illuminate some of the necessary pre-
cautions required when studying chromosomally engineered
mice. Expression levels of the genes within the trisomic
region (and in the companion monosomic mice) were
measured. Expression of the two genes at the end of the
triplicated or deleted region, ABCG1 and U2af1, was not
altered in monosomic, disomic, or trisomic mice. Ubash3a,
Tﬀ2, Tﬀ3, and Tmprss3 were expressed equally in mono-
somic and trisomic regions. The other genes in the region
were expressed according to gene dosage. The Umodl1 gene,
adjacent to the Abcg1 gene but not in the engineered region,
showed apparent increased expression in the thalamus, but
not in the hippocampus and cerebellum. These results
demonstrate the importance of analyzing chromosomally
engineered mice for unexpected eﬀects on expression of
genes near the rearranged chromosomal region.
3.1.6. Mice Trisomic (or Monosomic) for the Entire Mmu16,
17, and 10 Chromosomal Regions Syntenic to HSA21. It
could be argued that the ideal mouse model of DS would
be trisomic for all the mouse genes syntenic to HSA21
(i.e., the relevant parts of Mmu16, 17, and 10). A seminal
achievement has been accomplished via a process involving
production of mice trisomic for the relevant regions of
each mouse chromosome using chromosomal engineering
methods [29]. Then, mice trisomic for all three regions
were produced via selective breeding. These mice have many
features reminiscent of those seen in DS. Many of the
abnormalities in learning, memory and hippocampus are
very similar to those seen in the Ts65Dn mice.
The production of these mice allows examination of
the eﬀect of trisomy of each syntenic chromosome region
individually [81], resulting in some intriguing ﬁndings.
Dp(10)1Yey/+ mice, trisomic for the Mmu10 syntenic
region, did not have any detected alterations in learning and
memory behaviors or in hippocampal LTP. Trisomy of the
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in an increase in hippocampal LTP but no statistically
signiﬁcant change in learning and memory as assessed by
the Morris water maze or contextual fear conditioning. The
Dp(16)1Yey/+mice(trisomicfortheMmu16regionsyntenic
to HSA21), on the other hand, showed abnormalities in
hippocampal LTP and both the Morris water maze and
contextual fear conditioning tests similar to those seen in
the Ts65Dn mice. These results allow for some preliminary
conclusions regarding the Ts65Dn mice and demonstrate
the value of multiple mouse models. Speciﬁcally, since the
Dp(16)1Yey/+ and the Ts65Dn mice have similar pheno-
types, one could argue that the extra Mmu16 genes trisomic
in the Dp(16)1Yey/+ mice do not contribute to these aspects
oftheTs65Dnphenotype.Also,sincetheDp(16)1Yey/+mice
are not trisomic for any of the Mmu17 genes trisomic in
Ts65Dn, these genes are also unlikely to be important for
themeasuredphenotypicchanges.Finally,theminimaleﬀect
of the Mmu10 and 17 genes on the measured phenotypes
suggests that these genes are not major contributors to the
DS related phenotypes. However, these studies do provide
evidence that the various chromosome regions may interact
with each other, so care must be taken in making these
conclusions. One must also keep in mind that variations in
the tests used may lead to diﬀerent interpretations regarding
the relationship of the phenotype of these mice to DS. Also,
more complete characterization of these mice may yet reveal
that trisomy of the Mmu17 or 10 regions does lead to
phenotypic alterations relevant to DS.
One important phenotype of DS is congenital heart
defects. Considerable eﬀort has been spent attempting to
correlate partial trisomies of HSA21 with this phenotype
[73, 82]. Analysis of the mice described above indicates that
only the Mmu16 region is required to produce heart defects
in mice. In an elegant extension of this work, the region
associated with heart defects has been further delineated.
Mice carrying either a 5.43Mb duplication or the corre-
sponding deletion of a region extending from and including
the Tiam1 and Kcnj6 genes, Dp(16Tiam1-Kcnj6)Yey/+ and
Df(16Tiam1-Kcnj6)Yey/+, were produced by chromosomal
engineering [83]. These experiments, including breeding the
Dp(16)1Yey/+ mice with the Df(16Tiam1-Kcnj6)Yey/+ to
restore disomy of the genes in this region, demonstrate that
trisomyoftheTiam1-Kcnj6regionisnecessaryandsuﬃcient
to produce heart defects in mice. This approach is logically
similar to the approach of breeding trisomic mice with
knockoutsofindividualgenestoassesstheroleofthesegenes
in various DS phenotypes, described below.
3.1.7. Tc1 (Human Transchromosomal). Ac a v e a to ft r i s o m i c
mouse models is the possibility that increased dosage (“tri-
somy”) of HSA21 genes may produce diﬀerent phenotypic
eﬀects.Someinvestigatorshavearguedthatamouseinwhich
HSA21 has been stably introduced into the mouse genome
would be a better model of DS. In 2005, O’Doherty et
al. [84] reported the production of a mouse carrying an
HSA21 that was missing a small number of HSA21 genes.
This HSA21 was reported to have about 91% of the full
complement of HSA21 genes. The mouse has many features
seen in individuals with DS. However, so far, all Tc1 mice
are mosaics. That is, the chromosome is present in a variable
number of cells in any tissue. More recently, it has been
reportedthattheHSA21intheTc1mouseonlycontains81%
of the full complement of HSA21 genes [85]. In addition,
this chromosome apparently contains a duplication of the
S100β and PRMT2 genes [30]. Tc1 mice lose the extra
HSA21 chromosome on an inbred pure genetic background.
Moreover, some of the phenotypes of these mice depend
upon the genetic background of the animals. This is not
a surprising result and provides another cautionary note
regarding the use of mouse models.
3.2. Transgenic Mice. Transgenic mice contain additional,
artiﬁcially introduced foreign genetic material, often a single
gene, resulting in gain of function or overexpression of
a certain protein(s). The use of transgenic mice provides
an opportunity to study the biochemical and phenotypic
implications of overexpression of individual trisomic genes
in vivo. Molecular cloning of individual HSA21 encoded
genes allows analysis of their expression and organization of
their products and possible contributions to the DS pheno-
type. Features of transgenic mice that should be considered
include gene copy number, levels of transcription and pro-
tein expression, tissue speciﬁcity and timing of expression,
the site of integration of the transgene, and the genetic
background of the mice. Figure 1 shows the location of these
genes (indicated in bold) on HSA21 and the syntenic mouse
chromosome regions.
3.3. Transgenic Mice Possibly Related to Intellectual Disability
and Altered Brain Function in Individuals with DS. Several
genes on HSA21 have been found to be important for
neurodegenerative disorders, notably AD and amyotrophic
lateral sclerosis (ALS, or Lou Gehrig’s disease) or for synaptic
function and neurological development and degeneration.
3.3.1. APP. APP (aka AAA, AD1, PN2, ABPP, APPI, CVAP,
ABETA, PN-II, and CTFγ; App is the murine homolog)
encodes the amyloid beta (A4) precursor protein, which is a
cell surface receptor and transmembrane precursor protein.
Multipletranscriptvariantsencodingdiﬀerentisoformshave
been found for this gene. It is overexpressed in some
trisomic mouse models and in individuals with DS [86,
87]. APP is concentrated at the synapse in neurons and
may play a role in synapse formation and plasticity [88–
90]. Typically, APP undergoes extensive posttranslational
processing including phosphorylation, glycosylation, and
proteolysis. Normal APP proteolysis involves cleavage of the
extracellular domain by an α-secretase followed by cleavage
of the intermembrane domains by γ-secretase. The amy-
loidogenic pathway caused by abnormal cleavage of APP
by β-secretase leads to aggregation of beta-amyloid peptide
after cleavage by γ-secretase. The production of amyloid
plaques is considered a hallmark neuropathological feature
of AD. The protein is cleaved by secretases producing a
number of peptides. Some of the peptides are secreted
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to promote transcriptional activation. Other peptides are
components of the amyloid plaques found in the brains
of patients with AD. Mutations in this gene have been
implicated in autosomal dominant AD and cerebroarterial
amyloidosis. Early in life, individuals with DS begin to de-
velop progressive aggregation of beta-amyloid peptide and
AD-like neuroanatomical features.
Initially, transgenic models overexpressing wild-type
(WT) APP did not result in development of a neurodegen-
erative condition or AD-like pathologies such as amyloid
plaques. Though there are several WT APP transgenic lines,
only one appears to form plaques [91].
Using mice transgenic for WT human APP, Salehi et al.
[92] demonstrate that increased APP expression results in
a modest but signiﬁcant decrease in nerve growth factor
(NGF) transport.
Sim´ on et al. [93] show that overexpression of WT APP
in mice results in multiple pathological features, including
cognitive deﬁcits, severe histopathological abnormalities in
cytoskeleton, and signs of synaptic dysfunction, as well as
evidence of cell loss in the hippocampus and entorhinal
cortex. These alterations are accompanied by an early
increase in phosphorylated tau protein and elevated levels
of APP derived carboxy-terminal fragments but, remarkably,
almost undetectable levels of Aβ peptide. These results
strongly suggest the presence of Aβ independent pathogenic
pathways in AD.
The discovery of familial AD (FAD) mutations led to
the overexpression of mutant APP in transgenic mice that
does induce plaque pathology. These mice recreate many of
the pathologies associated with AD, including early-onset
AD as seen in DS. Overexpression of WT APP in DS is
associated with early onset AD [94]. Recently, it was found
that overexpression caused by APP gene duplication might
lead to FAD [95–97].
Overexpression of APP in these models is often at levels
far exceeding physiological levels, often up to 10-fold higher.
It has been suggested that overexpression of APP, or any
protein for that matter, at such high levels may be toxic.
In humans, amyloidopathy often results in a progressive
neurodegenerative condition; in mice this seldom is the case.
Though amyloidopathy does cause cognitive decline, it is
more reminiscent of natural aging or a predementia stage
rather than a complete neurodegenerative disease (reviewed
in [98]). In fact, the level of plaque load does not correlate
wellwithseverityofcognitivedeclineinpeoplewithAD[99].
The use of transgenic APP mouse models as models of
AD as well as models of aging is further discussed [98, 100,
101]. For a general list of transgenic APP, as well as other
models for neurodegenerative disease, the interested reader
is referred to the Alzheimer’s forum: http://www.alzforum.
org/res/com/tra/.
3.3.2. RCAN1. The regulator of calcineurin 1 gene (RCAN1,
aka CSP1, DSC1, RCN1, DSCR1, MCIP1, ADAPT78; Rcan1
is the murine homolog) encodes the calcipressin-1 protein,
which interacts with calcineurin A, and inhibits calcineurin-
dependent signaling pathways (such as activation of nuclear
factor of activated T-Cells (NFAT) transcription factors)
[102]. The gene is overexpressed in brain of DS fetuses.
RCAN1 is up regulated by calcineurin signaling, suggesting
regulation via a negative feedback loop. Calcineurin is an
ubiquitously expressed Ca2+-dependent phosphatase abun-
dant in both the developing and adult brain, heart, skeletal
muscle, and endocrine tissue [102–104]. It is responsible
for many Ca2+-dependent neuronal functions including
neurotransmitter release, neurite outgrowth, cytoskeletal
stabilization, and apoptosis (reviewed in [105]).
In trisomic mice, such as the Ts65Dn model, and in DS
fetal tissue, RCAN1 is increased by up to 1.8 fold possibly
aﬀecting CNS development [40, 104]. In individuals with
sporadic AD, RCAN1 is overexpressed in the cerebral cortex
and hippocampus, and chronic overexpression may lead to
neuroﬁbrillary tangles associated with AD pathology [104].
Ca2+ induces the expression of RCAN1 in a calcineurin-
dependent manner creating a negative feedback mechanism
causing sustained calcineurin repression [106]. Therefore,
the regulation of calcineurin by RCAN1 is of signiﬁcant
importance in the pathology of DS and AD.
TransgenicmicegeneratedusingahumanRCAN1cDNA
splice variant 1 under the control of the endogenous pro-
moter show a 4-fold increase in expression. Chromaﬃnc e l l s
takenfromthetransgenicmiceshowdisruptioninexocytosis
and vesicle traﬃcking mechanisms in a non-calcineurin-
dependent manner [107]. The authors make apparent that
these results are from a transgenic model with a 4-fold
increase in expression, which is much higher than the 1.5–2
fold increase typically found in individuals with DS.
A similar RCAN1 transgenic mouse was generated
under the control of the platelet-derived growth factor beta
(PDGFβ) promoter to drive expression in the brain [108].
These mice show a 1.3–1.5 fold overexpression in the hip-
pocampus and cerebral cortex along with poor performance
in the Morris water maze, indicating a disruption in visu-
ospatial learning. However, no diﬀerences in performance
of memory tasks were observed, suggesting once a task was
learned, retention was not impaired [108]. The authors
conclude that RCAN1 overexpression may contribute to
a disruption in the calcineurin-dependent phosphoryla-
tion/dephosphorylation balance in the hippocampus and
may inhibit learning, but not memory.
3.3.3. SYNJ1. Phosphatidylinositol-4, 5-bisphosphate is an
important intracellular signaling phospholipid and plays
essential roles in signal transduction, membrane traﬃcking,
and cytoskeletal dynamics [109–111]. Because it plays a
signiﬁcant role in several cellular signaling events, balance
at the cellular membrane is crucial. Phosphate kinase type-
1γ (PIPK1) and synaptojanin 1 (SYNJ1) are critical to main-
taining this balance at neuronal synapses [112, 113]. Synap-
tojanin 1 may act by dephosphorylating PtdIns(4,5)P2 and
may help stabilize PIPK1 [111, 113].
SYNJ1 is found on HSA21 and is trisomic in individ-
uals with DS [87, 114]. Considering the vital role SYNJ1
plays in cellular dynamics through PtdIns(4,5)P2 regulation,
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overexpression may result in neurophysiological changes
seen in DS and may contribute to early onset AD pathology
[115, 116]. Individuals with DS develop the pathology of
AD by their 3rd decade, possibly due to the overexpression
of APP and an increase in beta amyloid plaques [117].
Additionally, the overexpression of SYNJ1 due to trisomy of
HSA21 may render neurons more sensitive to the insults of
beta amyloid [116].
Transgenic mice were generated using BAC constructs
for both human and mouse SYNJ1 genes [115]. The human
and mouse SYNJ1 transgenic mice presented a 2.5-fold
increase in transcript levels and a 59% and 38% increase
in protein levels. Overexpression of SYNJ1 resulted in
altered PtdIns(4,5)P2 metabolism in the brains of these
mice. These authors suggest that given the pleiotropic
nature of PtdIns(4,5)P2, irregularities in the metabolism
of PtdIns(4,5)P2 could have signiﬁcant eﬀects on many
diﬀerent cellular functions. In addition to the altered
PtdIns(4,5)P2 metabolism, these mice exhibit poor per-
formance in the Morris water maze suggesting deﬁcits in
cognition and learning [115].
3.4. Transgenic Mice Possibly Related to the Altered Cancer
Spectrum in People with DS. Individuals with DS have
an altered spectrum of cancers. Speciﬁcally, there is a
signiﬁcantly increased risk of childhood leukemia and a
signiﬁcantly decreased risk of some solid tumors including
many for which incidence is age related [118]. Some trisomic
mice have similar features. Therefore, considerable work has
been done with transgenic and KO mice with altered levels of
genes encoded on HSA21 thought to be relevant to cancer.
3.4.1. ETS2. The v-ets erythroblastosis virus E26 oncogene
homolog 2 (avian) (ETS2, aka ETS2IT1; Ets2 is the murine
homolog) encodes protein C-ets-2, a transcription factor,
and is a prototype of the ETS family of transcription
f a c t o r s .T h eg e n ef o rE T S 2i sf o u n do nH S A 2 1 .T h eE T S
family of transcription factors activate or repress genes
responsible for cellular proliferation, diﬀerentiation, stem
celldevelopment,cellulartransformationandtumorigenesis,
cell senescence, and apoptosis [119]. The conserved ETS
domain within these proteins is a winged helix-turn-helix
DNA-binding domain that binds the core consensus DNA
sequence GGAA/T of target genes [120]. Ets2 is essential for
trophoblast development and is involved in establishing the
AP axis and paraxial mesoderm during development.
Overexpression of Ets2 has been shown to increase apop-
tosis and is linked to DS pathophysiology [121–123]. Ets2
transcription factors are found in neurons and seem to be
critical for neuromuscular junction formation in mice [124].
Mouse models with less than a 2-fold overexpression of
Ets2 show neurocranial, viscerocranial, and cervical skeletal
abnormalities reminiscent of trisomy 16 mouse models and
individuals with DS [125]. This model expresses the Ets2
cDNA transgene under the control of a metallothionein pro-
moter causing ubiquitous overexpression. These phenotypes
are reminiscent of physiological conditions of individuals
with DS and trisomic mice [125].
Using ETS2 transgenic mice, Wolvetang et al. [126]
show that the Ets2 transcription factors activate the APP
gene via speciﬁc Ets binding sites, acting cooperatively
with the AP1 transcription factor. Furthermore, brains and
primary neuronal cultures from ETS2 transgenic mice and
from ﬁbroblasts overexpressing ETS2 display abnormalities
reminiscent of DS such as elevated APP protein and beta-
amyloid production [126]. This may exacerbate the eﬀects
adverse eﬀects caused by APP overexpression in individuals
with DS.
3.4.2. RUNX1. The runt-related transcription factor 1
gene (RUNX1, aka AML1, CBFA2, EVI-1, AMLCR1,
PEBP2aB, and AML1-EVI-1; Runx1 is the murine homolog)
encodes runt-related transcription factor 1. RUNX1 is a
hematopoietic transcription factor associated with normal
hematopoiesis and megakaryopoeisis development [127,
128]. RUNX1 protein forms a heterodimeric transcription
complex with core-binding factor β (CBFβ). This complex
is the most common target observed in leukemia-associated
translocations, suggesting that it has an important role
in regulation of normal hematopoiesis. Children with DS
are more likely to develop leukemia, and 10% of children
with DS are born with transient megakaryoblastic leukemia
(TML), which often develops into acute megakaryocytic
leukemia (AMKL) [129]. RUNX1 is responsible for the ter-
minal diﬀerentiation of megakaryocytic progenitors. Muta-
tions, and translocations of RUNX1 are associated with
acute myeloid leukemias (AMLs) [128]. However, trisomy of
RUNX1 does not seem to be directly involved in TML or the
progression of AMKL in DS [130–132].
Transgenic mice expressing mouse Runx1 under the
control of the GATA1 hematopoietic regulatory domain
(HRD) were generated to determine the role of Runx1 in the
development myeloid leukemia in mice [133]. These mice
show roughly a ﬁve-fold overexpression of Runx1 transcript
and protein in whole bone marrow. It was determined that
a 5-fold increase in Runx1 did not initiate an increase
in leukemia. However, this group proceeded to cross the
transgenic Runx1 mouse with the BXH2 mouse model of
myeloid leukemia eﬀectively adding an additional copy of
Runx1. These mice show a decrease in the time period of
myeloid leukemia onset [133]. The overexpression of Runx1
in the Runx1-BHX2 cross is reminiscent of childhood DS,
AMKL, and similar to children with DS, this condition
was preceded by TML. However, these mice show a 5-
fold increase in Runx1 expression levels initiating TML and
AMKL, which to date has not been reported in children with
DS.
Interestingly, RUNX1 physically interacts with GATA1
[134].GATA1hasbeenshowntobedysfunctionalinchildren
with DS and in the development of AMKL [135–138]. It
has been suggested that an overdose of RUNX1 may render
GATA1 dysfunctional, and this may lead to the development
of AMKL in children with DS [139].
3.5. Mice with Genes Inactivated by Targeted Mutagenesis.
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function, and for determining whether or not a gene is
essential for viability. It is also useful for evaluating genes
via manipulation of gene dosage in the context of two
separate hypotheses; the “gene dosage eﬀect,” in which
abnormal expression of individual genes is responsible for
speciﬁc DS features, and “developmental instability,” in
which homeostasis is disrupted by chromosomal imbalance
and aberrant expression of many genes, resulting in develop-
mental abnormalities.
3.6. Knockout Mice Possibly Related to Intellectual Disability
and Altered Brain Function in Individuals with DS
3.6.1. APP. An App null mutant was generated via gene
targeting using a vector designed to replace the App pro-
moter, exon 1, and part of the ﬁrst intron with a neomycin
phosphotransferase gene (PGKneo) cassette [140]. Neither
App mRNA nor protein was detectable in App null animals,
however, these mice are viable and do not display any overt
abnormalities. Neuroanatomical analysis of brain tissue did
not show any signiﬁcant diﬀerences versus WT. However,
Heber et al. [141] demonstrated that the App functions
are indeed essential. App is one member of a gene family
including amyloid beta (A4) precursor-like protein 1 and
2 genes (Aplp1 and Aplp2). They demonstrate that mice
null for Aplp2 have no apparent abnormalities, but mice
null for both App and Aplp2 exhibit perinatal lethality,
indicating redundancy. They obtained similar results with
mice null for both Aplp1 and Aplp2, which suggests a critical
role for Aplp2. Mice null for both App and Aplp1 are
viable. Surprisingly, mice null for both App and Aplp2 show
no obvious histopathological abnormalities in brain, and
cortical neurons showed normal survival in basal culture.
Salehi et al. [92] demonstrated that, in Ts65Dn, there is
a marked decrease in nerve growth factor (NGF) transport
in hippocampus, resulting in down regulation of nerve
growth factor receptor (NGFR, or p75NTR) gene expression
and deterioration of basal forebrain cholinergic neurons
(BCFN). In Ts1Cje mice, there is a very mild decrease, when
compared to euploid mice. The authors hypothesize that
the marked decrease is due to trisomy of the App gene,
which is trisomic in Ts65Dn, but not in Ts1Cje. Crossing
Ts65Dn with a null allele for App (i.e., bringing the App gene
dosage from trisomy to disomy) partially rescues the NGF
decrease. Consistent with this observation, mice transgenic
for a human APP allele, which expresses the gene at levels
comparabletolevelsinDS,showa(relativelymild)reduction
in NGF transport.
These observations suggest that trisomy of App is largely,
but not exclusively, responsible for the decrease in NGF
transport and the resulting reduction in BCFN seen in
Ts65Dn. Mice transgenic for both APP and presenilin 1
(PSEN1, or PS1) show further reduction in NGF transport
and in BCFN number, indicating an additive eﬀect, further
supporting this hypothesis. Early endosomal alterations are
the earliest known pathology in sporadic AD and DS [142].
These alterations appear before birth in DS, and in AD, prior
to the deposition of β-amyloid and as soluble Aβ levels ﬁrst
rise. Thealterationshavebeenobservedin thehippocampus,
neocortex, and basal forebrain.
The endosomal alterations are seen in Ts65Dn mice, but
are not seen in Ts1Cje mice (which are disomic for App),
or in Ts65Dn disomic for App (Ts65Dn, App+/+/−), which
indicates that increased App expression is required for the
alterations. However, the alterations are not present in mice
transgenic for either the human APP London (APP670/671
plus APP717) or Swedish (APP670/671) mutations. Both
mutations result in high expression of APP (two fold for
the London transgenic, and seven fold for the Swedish
transgenic). These results indicate, collectively, that App
overexpression is necessary, but not suﬃcient for producing
the alterations; overexpression of one or more additional
MMU16 genes trisomic in Ts65Dn is required. The endoso-
mal alterations may be at least partially due to reduction in
NGF transport [143].
3.6.2. RCAN1. An Rcan1 null allele was generated by gene
targeting using a vector designed to replace exons 5 and 6
withβ-galactosidase[144].Null(−/−)Rcan1miceareviable
andfertile,andexhibitnoovertabnormalities.Northernblot
analysis demonstrates that the null allele does not produce
detectable transcript.
Calcineurin has been shown to be necessary and suf-
ﬁcient for cardiac hypertrophy, in response to various
physiological and pathological stimuli. KO mice lack-
ing the calcineurin A β catalytic subunit exhibit dimin-
ished response to hypertrophic stimuli. Since calcipressin-1
inhibits calcineurin-dependent signaling, increased expres-
sion of calcipressin-1 would be expected to reduce the hyper-
trophy response, and decreased expression should increase
hypertrophy. Consistent with this expectation, Rcan1 null
mice carrying a muscle-speciﬁc transgene expressing acti-
vated calcineurin showed an exacerbated hypertrophic
response, and severe ﬁbrosis. Unexpectedly, cardiac hyper-
trophy was reduced in null mice in which the hypertrophic
stimulus was due to aortic banding, or chronic adrenergic
stimulation. This suggests that calipressin-1 may have a dual
role in cardiac hypertrophy, dependent on diﬀerences in
hypertrophic stimulation.
Rcan1 is expressed in mouse in developing brain and
craniofacial structures. It is trisomic in several DS mouse
models, including Ts65Dn, Ts1Cje, and Ts16. Ts16 embryos
exhibit high incidence of cardiac valvuloseptal malforma-
tions and abnormal development of the brain, skull, and
sensory organs. However, mice trisomic for a Mmu16
region syntenic to an HSA21 region (Ts1Rhr [75]), but
not including the Rcan1 locus (among other loci), do not
develop cranial dysmorphologies, suggesting the possibility
that overexpression of Rcan1 may be partially or fully
responsible for these phenotypes.
Lange et al. [145] evaluated expression of Rcan1 in
the Ts16 mouse model and show that expression of Rcan1
isoforms is increased in developing heart and brain, versus
diploid littermates, while NFAT transcriptional activity is
decreased. To evaluate the role of Rcan1 in Ts16 trisomy,
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[144] to restore the Rcan1 locus to disomy, in the Ts16
background. Examination of these mice demonstrates that
restoring Rcan1 to disomy in Ts16 mice does not rescue
cardiac and craniofacial abnormalities.
Ithaslongbeenknownthattheincidenceofmanycancer
types (typically solid tumors) is reduced in individuals with
DS, and this protection is thought to be due to increased
expression of one or more of the chromosome 21 genes that
are trisomic in DS. RCAN1 suppresses vascular endothelial
growth factor- (VEGF-) mediated angiogenic signaling via
the calcineurin pathway. Baek et al. [40] demonstrated that
RCAN1 is expressed about 1.8 fold higher in DS fetal
tissues, and Rcan1 is expressed about 1.7 fold higher in
Ts65Dn mice. They tested two tumor models, Lewis lung
carcinoma and B16F10 melanoma, in Ts65Dn mice, and
observed considerable tumor growth suppression relative to
WT, accompanied by a decrease in microvessel density. They
obtained similar results using an Rcan1 transgenic mouse,
and also noted a signiﬁcant decrease in CD31+CD45− cells
(CD31 is an endothelial marker, CD45 is a hematopoietic
marker) versus WT. Inoculation of transgenic and WT mice
with reduced numbers of Lewis lung carcinoma cells to
generateslowlygrowingtumorsdemonstratedthatincreased
Rcan1 expression inhibits the initial expansion as well as
extended growth of transplanted tumors, indicating inhibi-
tionofbothneoangiogenesisandco-optionofexistingblood
vessels.
Matings were performed to produce Ts65Dn/Rcan1+/+/−
mice, which exhibit signiﬁcantly abrogated tumor protection
along with increased microvessel density, demonstrating that
Rcan1 overexpression plays an important role in these pro-
cesses [40]. Since increased Rcan1 dosage attenuates VEGF-
calcineurin-NFAT signaling, the authors examined the role
of Dyrk1A, which is also trisomic in DS and Ts65Dn, and
regulatesNFATsignaling.Theydemonstratethatoverexpres-
sion of both Dyrk1A and Rcan1 in endothelial cells results
in greater inhibition of VEGF-mediated endothelial prolif-
eration than in cells overexpressing Rcan1 alone, suggesting
that Dyrk1A may be responsible for the increased tumor
suppression observed in Ts65Dn/Rcan1+/+/− versus WT.
3.6.3. Synj1. A Synj1 null allele was generated by gene
targeting using a vector designed to replace 103 base pairs
(bp) from the 3  portion of the ﬁrst coding exon, and
1571bp of the adjacent intron with a neomycin resistance
cassette [109]. Mice heterozygous for the null allele are
phenotypicallynormalandfertile.Crossesbetweenheterozy-
gotes produce pups with the expected genotypes, at the
expected Mendelian ratio. However, within a few hours, the
homozygous null pups become distinguishable from their
littermates by the severe reduction in the amount of milk
in their stomachs. About 85% of the homozygous null mice
die within 24hours, and the remaining 15% die within 15
days. The latter group exhibit reduced growth, with a 3-fold
diﬀerence versus littermates at 10 days, and they develop
severe weakness, ataxia, and generalized convulsions that can
be evoked by the tail ﬂick test. These results clearly indicate
that the gene is essential for postnatal development. The
absence of Synj1 expression did not alter the expression
of a large variety of nerve terminal proteins, including
synaptojanin 1 interactors, proteins thought to play a role
in synaptic vesicle endocytosis, intrinsic membrane proteins
of synaptic vesicles, plasma membrane t-SNAREs, additional
proteins thought to play a role in the synaptic vesicle cycle,
and enzymes involved in phosphoinositide (PI) metabolism.
The authors demonstrate a 1.6-fold increase of
PtdIns(4,5)P2 in cultured cortical neurons from null mice
versus WT, but no major diﬀerences in PtdIns(4)P (they
were unable to detect other PI species), and that the increase
in PtdIns(4,5)P2 is due to a reduction in dephosphorylation
of PtdIns(4,5)P2 to PtdIns(4)P. Electron microscopy of
cultured cortical neurons showed an increased number of
clathrin-coated vesicles localized around the synaptic vesicle
cluster, and that the great majority are isolated vesicles
(separated from the plasma membrane). The PI binding
properties of clathrin coat proteins suggest that the increased
number of clathrin-coated vesicles is due, at least in part,
to increased PtdIns(4,5)P2. Similar results were obtained
in cell-free assays in which protein-free liposomes from
crude brain lipid extracts were incubated in brain cytosol
plus ATP and GTP. Cytosol from null animals produced a
4-fold higher number of coated vesicles than WT cytosol.
Biochemical analysis showed a larger pool of clathrin and
AP-2 bound to liposomes incubated with the null cytosol.
This diﬀerence was counteracted by addition of puriﬁed
synaptojanin 1 to the null cytosol.
Electrophysiological analyses of hippocampal slices from
10-day-old animals suggest that basal properties of synaptic
transmission are unchanged in null mice, but that regen-
eration of a releasable pool for synaptic vesicle release is
diminished in hippocampal synapses from null animals
resulting in a depression of synaptic response. The authors
suggest that the absence of synaptojanin 1 may aﬀect
actin dynamics as well (PI are important regulators of the
actin cytoskeleton), resulting in trapping of clathrin-coated
vesicles within an actin matrix.
The expression of Synj1 in Ts65Dn brain is about
40% greater than in controls as measured by quantitative
western blot [115]. This overexpression in Ts65Dn results
in a 33% increase in the production of phosphatidylinositol
monophosphate (PtdInsP) relative to controls in a brain
cytosol assay, using NBD-PtdIns(4,5)P2, a ﬂuorescently la-
beled water-soluble substrate. Reducing the copy number of
Synj1 to disomy in Ts65Dn results in reduction of PtdInsP
production to control levels. Similarly, HPLC analysis with
suppressed conductivity detection demonstrates a ∼16%
decrease in the mass of PtdIns(4,5)P2 in Ts65Dn brain rel-
ative to controls. The decrease was fully corrected in brain
from Ts65Dn mice disomic for Synj1. Finally, in metabolic
labeling studies of phospholipids in cortical synaptosomes,
they demonstrate a ∼30% decrease in the PtdInsP2/PtdA
ratio in Ts65Dn versus controls. The authors suggest that
increased expression of Synj1 may play a role in the learn-
ing deﬁcits observed in Ts65Dn mice. As stated above
(Section 3.3.3), the authors demonstrate a learning deﬁcit, as
evaluated by the Morris Water Maze test, in mice transgenic
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they did not evaluate Ts65Dn mice disomic for Synj1, al-
though they do state that performing this experiment is
essential [115].
3.7. Knockout Mice Possibly Related to the Altered Cancer
Spectrum in People with DS
3.7.1. ERG. The v-ets erythroblastosis virus E26 oncogene
homolog (avian) gene (ERG, aka p55, and erg-3; Erg is the
murine homolog) encodes transcriptional regulator ERG, a
member of the erythroblast transformation-speciﬁc (ETS)
family of transcription factors.
ERG is involved in chromosomal rearrangements in
myeloid leukemia, in 5 to 10% of cases of Ewing’s sarcoma,
resulting in fusion of Erg and a member of the Tet subfamily
of RNA-binding proteins. ERG is deleted in a subset of acute
lymphoblastic leukemias, which may facilitate transforma-
tion, and is suggestive of a role for ERG in DS childhood
leukemia. Chromosomal rearrangements result in control of
ERG expression by the androgen-responsive 5  elements of
TMPRSS2 in more than half of all prostate cancers. Thus,
there is strong evidence that ERG has an important role in
hematopoiesis, and that it is a potent oncogene. So far, no
ERG transgenic mice have been reported.
A germline mutation of Erg, designated ErgMld2,w a s
obtained via a genetic screen for regulators of hematopoietic
stem cell function [146]. Direct sequencing revealed that the
mutation is a thymidine to cytosine transition in exon 12,
causing a substitution of proline for serine at residue 329
in the ﬁrst α-helix of the DNA-binding Ets domain. Pulse
chase experiments in a human embryonic kidney cell line
indicated the mutant protein has a half-life similar to that
of WT Erg, suggesting that it is stable in vivo.E l e c t r o p h o r e t i c
mobility-shift assays using radiolabeled DNA and titration
with cold competitor DNA show that the mutant retains
DNA binding ability and binds the E74 enhancer element
(a known Erg-binding site) with an aﬃnity similar to the
WT protein. However, reporter assays demonstrate that the
mutant’s ability to transactivate transcription is negligible,
and that it cannot promote megakaryocyte diﬀerentiation
when expressed in human erythroleukemic cell line K562.
No ErgMld2/Mld2 mice from matings of mice heterozygous
for the ErgMld2 allele were identiﬁed at weaning, indicating
the homozygous mice were probably dying during embryo-
genesis. Analysis of embryos from timed matings shows that
homozygous mice are viable at day E10.5, some were dead at
E11.5, and none were alive at E13.5. Homozygous embryos
at day E10.5 exhibit developmental delay, and culture of yolk
sacs from these embryos yielded almost no hematopoietic
progenitor-derived colonies of any lineage, demonstrating
failure of deﬁnitive hematopoiesis in the ErgMld2/Mld2 mice.
Mice heterozygous for the ErgMld2 allele have lower
blood platelet numbers than WT, but are not anemic.
Histopathology of tissues from adult thymus, spleen, bone
marrow, pancreas, lymph nodes, liver, kidney, bladder, small
bowel, skin, skeletal muscle, salivary gland, or femur showed
no gross abnormalities. Culture of single-cell suspensions of
bone marrow and spleen yielded fewer colonies than WT,
and the frequency of progenitor cells of all lineage types
was about 50% that of control littermates. Colony-forming
assays demonstrate that mice heterozygous for the ErgMld2
allele have fewer committed hematopoietic progenitors and
multipotent cells, and a smaller population of lineage-
negative Sca-1+c-kit+ (LSK) cells (representing long-term
repopulating hematopoietic stem cells and early hematopoi-
etic progenitors).
Ts65Dn mice at 12 months of age exhibit progressive
thrombocytosis, megakaryocytosis, and megakaryocytic dys-
plasia within bone marrow, extra medullary hematopoiesis
in spleen with disrupted splenic architecture, and so forth
[147]. Breeding the ErgMLD2 mutation into the Ts65Dn
background to produce mice disomic for ERG results in
amelioration of histopathologic myeloproliferative features
to WT levels. Interestingly, Ts1Cje mice, although trisomic
for Erg, do not develop myeloproliferative disorder, suggest-
ing that Erg is necessary, but not suﬃcient, for the Ts65Dn
myeloproliferative features.
3.7.2. ETS2. An Ets2 allele (ets2db1) was produced by gene
targeting using a vector designed to replace all or part of
three exons of the gene coding for the Ets2 DNA binding
domain with pMC1NeoA [148], resulting in deletion of
a critical portion of the gene (a large fusion transcript
is observed), and production of a truncated protein that
binds to an Ets2 antibody [149]. Mice homozygous for the
allele are not obtained from heterozygous matings due to
a defect in formation of extraembryonic tissues. They can
be obtained via complementation using tetraploid embryos
(which produce functional extraembryonic tissues) [150].
At birth, ets2db1 homozygous mice exhibit curly
whiskers.After∼2weeksofage,inadditiontocurlywhiskers,
the mice exhibit wavy hair, and a slightly rounded forehead.
Whole mount analysis of skin shows misalignment of hair
follicles,resultinginingrowncurlyhairsthatfailtopenetrate
theepidermis.MicedeﬁcientforTGFαandmicewithapoint
mutation in the EGF receptor have a similar whisker-hair-
hair follicle phenotype. The mice are fertile, and lymphoid
and myeloid cell development is not signiﬁcantly diﬀerent
from WT.
An Ets2 hypomorphic allele (Ets2A72) was produced by
knock in gene targeting, in which the threonine target of
Erk phosphorylation is replaced by alanine [151]. Ets2A72
homozygous mice exhibit normal fertility and longevity.
They do not develop the hair and hair follicle abnormalities
found in rescued Ets2db1 homozygous mice. Histological
analysis of 50 organs did not reveal any unusual abnormali-
ties. Mammary gland development in females is normal.
Since Ets2db1 homozygous mice die due to placental
insuﬃciency, Wei et al. [152] employed the Ets2A72 allele
to produce an Ets1/Ets2 double “null” to investigate the role
of both genes in the ras/Raf/Mek/Erk pathway and prevent
rescue of the individual null phenotypes. Mutations in both
genes result in abnormal angiogenesis in development, and
full lethality by about day E14.5 (Ets2 nulls (db1 and ﬂ)
acting essentially the same as mutated Ets2 (A72)). Both
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genes are proto-oncogenes and may act in endothelial cells
to aﬀect tumor angiogenesis.
Misregulation of ETS2 is associated with cancer, and
some studies suggest that increased dosage of ETS2 in DS
contributes to a reduced risk of cancer [126]. Ts65Dn mice
are trisomic for Ets2. In an elegant series of experiments,
Sussan et al. [153] demonstrated that trisomy of Ets2 in
Ts65Dn and Ts1Rhr mice suppresses the occurrence of
intestinal tumors when these mice are bred with the ApcMin
mice that have a highly increased incidence of intestinal
tumors. These studies are consistent with the proposed role
of ETS2 in reducing tumor incidence in DS. As mentioned
above, Ts65Dn mice develop cranial skeleton and thymus
anomalies. Similar anomalies were seen in transgenic mice
that constitutively overexpress a processed Ets2 transcript
under metallothionein promoters. To evaluate the role of
native Ets2 in the craniofacial and thymus phenotypes of DS,
Hill et al. [36] used these mice to show that the reduction
in Ets2 expression in these mice does not rescue thymus
abnormalities, and mostly does not rescue cranial skeleton
abnormalities, except for mesoderm-derived elements (the
superoinfero height of the occipital bone is reduced by 16%
in Ts65Dn, Ets2+/− versus euploid but is reduced by 4% in
Ts65Dn versus euploid). These experiments conﬁrm a role
forEts2inthesuppressionoftumorsinDS,butEts2doesnot
play a major role in skeletal or thymus abnormalities seen in
Ts65Dn mice.
3.7.3. RUNX1. A Runx1 null allele was generated by gene
targeting using a vector designed to replace the splice
acceptor and ﬁrst 20 bp of the exon encoding the central 52
amino acids of the Runt homology domain (RHD, required
for DNA binding) with a hygromycin B cassette [127].
Homologous recombination also introduces stop codons in
all three reading frames, ensuring production of a truncated
protein.
Mice heterozygous for the null allele are apparently
normal, exhibiting no diﬀerence in hematocrits, nucleated
blood cell counts, white blood cell diﬀerentials, or distribu-
tion of peripheral blood lymphocyte subsets as analyzed by
ﬂuorescence-activated cell sorting analysis (FACS). However,
homozygous nulls die during embryogenesis at about day
E12.5. Morphological evaluation of E12.5 null embryos
shows extensive hemorrhaging within the ventricle of the
central nervous system and the vertebral canal, which
appears to originate in the ganglia of the cranial nerves,
extendingintothethirdandlateralventricles.Hemorrhaging
wasalsoobservedinthepericardialspaceandperitonealcav-
ityinmostnullanimals.AtE11.5,about87%ofnullembryos
are viable, and are indistinguishable from heterozygous or
WT embryos, except for a slight liver pallor. Microscopic
examinationofnullembryoliveratday11.5indicatesacom-
plete absence of liver-derived hematopoiesis. No erythroid,
myeloid, or megakaryocyte cells were identiﬁed, and only
primitive nucleated erythrocytes were observed in vascular
channels and hepatic sinusoids. Runx1 null embryonic stem
cells can diﬀerentiate into primitive erythroid cells in vitro,
but no hematopoietic colonies were obtained in cultures
from yolk sac or liver from null embryos, demonstrating that
Runx1 is essential for liver hematopoiesis.
Hematopoiesis was not well characterized in Ts65Dn
mice, except for one report demonstrating decreased pro-
liferation of CD34+ cells in vitro [154]. Kirsammer et
al. [38] investigated hematopoiesis in Ts65Dn mice and
demonstrate that they develop highly penetrant progressive
myeloproliferative disease characterized by thrombocytosis,
mild anemia, extramedullary hematopoiesis, bone marrow
ﬁbrosis, and distorted stem and myeloid progenitor com-
partments, and they note that the phenotype resembles
human chronic idiopathic myeloﬁbrosis (the incidence of
which increases with age [155]). To elucidate the role, if
any, of increased expression of Runx1, they employed a
breeding strategy involving the Runx1 null allele [127]t o
produce Ts65Dn mice disomic for Runx1. They conclude
that increased dosage of Runx1 is not required for develop-
ment of megakaryocytic hyperproliferation, extramedullary
hematopoiesis, and reticulin ﬁbrosis observed in Ts65Dn
mice.
Carmichael et al. [156] investigated hematopoiesis in
Ts1Cje mice which, as discussed above, are trisomic for a
smaller region of Mmu16 than that in Ts65Dn mice. Ts1Cje
exhibits a hematopoietic phenotype similar to that observed
in Ts65Dn mice, except Ts1Cje mice do not show any sign
of development of thrombosis or myeloproliferative disease.
This suggests strongly that trisomy of one or more genes
within the trisomic region unique to Ts65Dn is responsible
for development of thrombosis and myeloproliferative dis-
ease, while the other hematopoietic abnormalities are largely
caused by trisomy of genes in the trisomic region common
to both Ts65Dn and Ts1Cje.
4. Conclusions
Recent progress in methods for producing genetically altered
mice demonstrates that it is now possible, at least in theory,
to produce mice trisomic for any gene found on HSA21 or
any mouse chromosomal region syntenic to HSA21, and KO
mice for any HSA21 syntenic gene(s). Indeed, a large inter-
nationaleﬀort is underway to produce KO mice for all mouse
genes and to assess their phenotypes. Moreover, and equally
important, it is possible to completely characterize the
genetic alterations in the various mouse models, including
alterations in gene number, expression, and structure, which
is essential for proper interpretation of the consequences
of trisomy of particular genes or chromosomal regions.
This capability presents an unprecedented opportunity for
unraveling the mechanisms of DS pathogenesis and, on the
basis of this information, devising rational therapies for
alleviation of the deleterious consequences of Trisomy 21.
The analysis of various mouse models to date allows
some preliminary conclusions. By far, the most well-
characterized mouse model phenotypically is the Ts65Dn
mouse. Considerable evidence suggests that Ts65Dn mice
exhibit aspects of aging relevant to DS. Interestingly, even
though Ts65Dn mice are trisomic for about 60 Mmu17
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HSA21, their phenotype is remarkably similar to that of the
Dp(16)1Yey/+ mice that are trisomic for the entire Mmu16
region syntenic to HSA21, and that have no additional
trisomic genes. Of course, diﬀerences may be revealed as the
mice are more thoroughly characterized. This observation
does not mean that HSA21 genes found on Mmu10 or
Mmu17 are irrelevant for DS. For example, the Mmu10 or
17 regions may ameliorate some of the eﬀects of trisomy of
the Mmu16 region.
In general, analysis of transgenic and KO mice reveals
phenotypes consistent with a given gene’s known function
and in some cases have helped in elucidating its function.
Also, when KO mice have been bred with trisomic mice,
reducing a gene’s copy number from three to two, the
observedeﬀectshavebeenconsistentwiththegene’sfunction
as determined by other studies.
Often, the point has been brought up that the genetic
background of the various mouse models is critical, since
response to trisomy may diﬀer depending on this parameter.
One should keep in mind, however, that people with DS
are certainly not inbred, and an eﬀect seen in a noninbred
mouse strain or in multiple genetic backgrounds may be
more relevant to the human situation than eﬀects observed
in inbred models. It is also important to assess phenotypes in
more than one mouse model where possible.
5. FutureDirections
The results from studies of genetically altered mice, coupled
with the ability to produce essentially any mouse model,
demonstrate that this approach will play a key role in
understanding the DS phenotype, as well as phenotypes
related to the biology of aging in people with DS. Studies
so far make it clear that the genetic alterations in mouse
models can be precisely deﬁned with regard to gene content
and alterations in gene expression. Results from studies
in which dosage of speciﬁc genes in segmentally trisomic
mice is reduced to disomy via breeding with relevant KO
mice suggests that this is a particularly fruitful approach.
As KO mice for more genes become available, the pace of
these experiments should accelerate. This approach appears
to be more successful in revealing a gene’s role in DS
than the creation of single-gene transgenic mice. However,
the production of transgenic mice to assess the eﬀects of
trisomy of speciﬁc genes, especially genes associated with a
particular disorder, or for which a particularly compelling
hypothesis suggests they may have a signiﬁcant eﬀect, may
be worthwhile. Also, there may be strong justiﬁcation for
increasing the dosage of syntenic Mmu10 and 17 genes to
trisomy in mice trisomic for Mmu16 regions.
The observation that segmental trisomy for Mmu10
and Mmu17 regions syntenic to HSA21 have relatively
minor phenotypic eﬀects appears to limit the regions of
HSA21 important in DS. However, this interpretation may
not yet be warranted. First, it is possible that continuing
characterization of the various segmental trisomy mice may
reveal phenotypes relevant to DS that are caused or aﬀected
by genes located in these regions. Moreover, it may be that
trisomyoftheseregionsinteractswithtrisomyoftheMmu16
syntenic region, aﬀecting the Mmu16 trisomic phenotype.
Ts65Dn and other segmental trisomy mouse models
serve as treatment models for some aspects of DS, and agents
showing a beneﬁcial eﬀect in these mice are either in human
clinical trials or will be soon on the basis of their success in
ameliorating the symptoms in these models. This brings up
an interesting and critical question, namely, is the approach
of using particular mouse models valid in preclinical studies,
especially when the mechanism of action of a given agent
is poorly understood? One could argue that if a particular
agent improves a deleterious phenotype reminiscent of those
seen in people with DS, this should be suﬃcient justiﬁcation
for proceeding with human trials. This perspective is prob-
lematic in some ways. For example, it is possible that genes
on the HSA21 syntenic Mmu10 or 17 regions will inﬂuence
the result of drug treatment. For example, individuals with
DS show an increased sensitivity to cytosine arabinoside
and this may help explain the high event-free survival rates
seen in treatment of people with DS who have developed
AML.Thisincreasedsensitivityisattributed,atleastpartially,
to trisomy of the CBS gene, located on Mmu17 in mice.
Similarly, individuals with DS show a signiﬁcantly increased
sensitivity to methotrexate, one of the most widely used
anticancer drugs, and this may be due to trisomy for the
Slc19a1 (reduced folate carrier) gene, which is on Mmu10
[15]. It would be interesting to determine whether making
Ts65Dn mice trisomic for CBS or for RFC would increase
their sensitivity to cytosine arabinoside or methotrexate,
respectively. The appropriate transgenic mice already exist
and have been partially characterized. In general, the more
one knows about the mechanism of drug’s action, the more
eﬀectively one may be able to test it in appropriate mouse
models. Therefore, mechanistic studies of the eﬀects of
possible therapies using mouse models would be extremely
worthwhile.
It is reasonable to expect that therapies to improve
intellectual and other disabilities associated with DS and/or
aging will soon become available. Mouse models of DS will
have played a critical role in this development, and it is
virtuallycertainthattheywillcontinuetodoso.Thus,mouse
models will have made a major contribution to the lives of
individuals with DS and their families. Moreover, any feature
seen in individuals with DS is also seen in the population
without DS. Therefore, use of these mouse models will likely
have beneﬁcial eﬀects far beyond the population with DS.
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